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Introduction {#sec005}
============

Clinical and scientific background {#sec006}
----------------------------------

In the perioperative treatment of patients undergoing intracranial surgery, we are caught between two stools: the need for prophylactic AC and its most feared adverse effect, intracranial hemorrhage. As the latter is always a life-threatening event, with a mortality rate between 18 and 32% \[[@pone.0238387.ref001], [@pone.0238387.ref002]\], neurosurgeons naturally tend to avoid perioperative AC as much as possible \[[@pone.0238387.ref002], [@pone.0238387.ref003]\]. Neurosurgical patients are at high risk of thromboembolism due to immobilization and the long duration of surgery. Additionally, with cardiovascular diseases becoming more prevalent owing to demographic changes, increasing numbers of significantly anticoagulated patients are to be observed \[[@pone.0238387.ref004]\]. A survey conducted by Skardelly et al. concluded that in 2016, nearly two thirds of German neurosurgical departments had not yet defined an algorithm for continuous, discontinuous or bridged anticoagulant and antiplatelet therapy during elective surgery. Therefore, treatment standards for patients at individual risk of TE vary widely among different centers. In some cases, altering, pausing, or stopping their blood thinning regimen prior to intracranial surgery puts them at high risk of TE \[[@pone.0238387.ref005]\].

Owing to the lack of sound data, the decision regarding the type, dose and time point for perioperative prophylactic anticoagulation is frequently based on clinical experience, estimated risk, and interdisciplinary discussion between cardiology, intensive care practitioners, and neurosurgeons. Relevant indications (e.g. aortic valve replacement, atrial fibrillation, stents), risk factors for TE (immobilization, prolonged duration of surgery, prone position during surgery, coagulopathy, malignant diseases, infection, comorbidities, history of TE, old age, hemiparesis or hemiplegia) \[[@pone.0238387.ref002], [@pone.0238387.ref003], [@pone.0238387.ref006]--[@pone.0238387.ref012]\] are weighed against risk factors for PH (intraoperative bleeding tendency, size and vascularization of the tumor, entity, prolonged operative time, metabolic syndrome). The variety of risk factors and intra-individual differences regarding tumor morphology, AC, and corresponding indication is vast \[[@pone.0238387.ref001], [@pone.0238387.ref002], [@pone.0238387.ref006]--[@pone.0238387.ref008], [@pone.0238387.ref013]\]. Therefore, our study focused on the search for independent yet widespread, easily measurable risk factors for PH and TE in patients with cranial meningiomas.

Objective and outlook {#sec007}
---------------------

In this paper, we present retrospective data on perioperative anticoagulation in meningioma surgery. We aim to improve safe perioperative prophylactic AC management and contribute to guidelines and standards.

Patients and methods {#sec008}
====================

Patient selection and treatment {#sec009}
-------------------------------

We searched the digital database of University Hospital Leipzig for all patients diagnosed with meningioma who had undergone surgery between 2012 and 2018 and been operated on at the Department of Neurosurgery, University Hospital Leipzig. We included 286 patients with no exclusions. Data acquisition was approved by the ethics committee of the Medical Faculty, University of Leipzig (No. 053/19-ek). All patient data were fully anonymized. Being an anonymous retrospective review with no personal data, the ethics committee did not require informed consent.

Exclusion criteria included missing documentation or inconclusive data on the perioperative AC regimen as well as age below 18 years. Patients lost to or without follow-up within 30 days were excluded for acute treatment evaluation.

All tumor cases in our neurooncological center were discussed in a weekly, interdisciplinary tumor board. The therapy regimen regarding operative resection or conservative treatment was decided in interdisciplinary discourse based on international guidelines \[EANO\].

Patients were anticoagulated in accordance with national guidelines \[[@pone.0238387.ref014], [@pone.0238387.ref015]\], known independent risk factors, and pre-existing diseases. The time point and dose as well as the choice of substance were decided according to the hospital's guidelines and in interdisciplinary bedside discourse with intensive care and neurosurgical practitioners. The fact that anticoagulation did not follow a definite protocol resulted in the variety of time points and therapy regimens examined in this study. However, the common course of treatment and diagnosis can be described as follows.

Patients are not anticoagulated until a CT scan has been performed. CT scans on the first postoperative day are routine (within 24h after surgery). CT scans are performed immediately following the onset of new neurological deficits.

We begin prophylactic AC treatment in patients undergoing intracranial surgery on the first day after surgery, as long as postoperative CT scans do not show any signs of residual bleeding. Patients with postoperative or perioperative hemorrhage are mainly anticoagulated after 3--5 days following a repeat CT scan without any sign of a growing hemorrhage.

In patients with a preoperative regimen of DOAC or NOAC, therapy was interrupted for up to 3 weeks depending on indications during the period concerned. In these cases, heparin bridging was regularly performed.

Since 2014, a standard operating procedure has stated that hospitalized tumor patients should be considered for anticoagulation as long as there are no contraindications, in which case either mechanical prophylaxis or no prophylaxis at all should be applied. We have adapted this regimen and currently halt pre-existing AC until the removal of sutures if there are no urgent indications.

Assessed data {#sec010}
-------------

Laboratory values were assessed at the time of admission, as were minima and maxima. PH was assessed as an adverse event (0 = did not occur, 1 = occurred), and also classified regarding the need for surgical intervention. TE (i.e. mesenterial emboli, pulmonary emboli, deep vein thrombosis, cerebral or myocardial infarction) were classified accordingly (0 = did not occur, 1 = occurred). We distinguished between the localization of embolism for further analysis.

Selected parameters:

Biographical: Age, gender, weight, height, smoker, pre-existing anticoagulation (indication and regimen).

Laboratory charts: pTT, INR, blood pressure, platelet count, hematocrit, creatinine, sodium, white blood cell count, indicators for coagulopathy.

Treatment: Postoperative anticoagulation, time point of treatment initiation, prevalence of hemorrhage and embolism, regimen (dose/substance/application). Antiplatelet therapy was evaluated, but temporarily paused in all cases.

Peri-operative: General anesthesia, steroid treatment, dialysis, duration of surgery, type of procedure/bleeding, GOS/mRS after surgery.

End points: Postoperative hemorrhage (CT morphological) with or without revision, pulmonary emboli, thrombosis (vein or peripheral), death, readmission (30 days).

Statistical analysis {#sec011}
--------------------

Continuous parameters are displayed as median with standard deviation and interquartile range and were analyzed with Welch's Test, t-test and Mann--Whitney U test (although only the Mann--Whitney U test was used for GOS and mRS as ordinal variables).

Dichotomous parameters are shown as number and percentage, and statistically compared using chi-square or Fisher's exact tests.

P-values lower than 0.05 were considered statistically significant.

Odds ratios (OR) and their confidence interval of 95% were computed using univariate binomial logistic regression. Parameters which appeared relevant for the occurrence of TE or PH in univariate analysis were included in multiple logistic regression. We attempted to find the model with the best fit. Collinearity between the independent variables was tested using the variance inflation factor (VIF). The Hosmer--Lemeshow test was applied to confirm calibration.

All analyses were completed using IBM SPSS Statistics Version 24 (IBM, Armonk, New York State, USA).

Results {#sec012}
=======

A total of 286 patients with intracranial meningioma who had been operated on in the Department of Neurosurgery between 2012 and 2018 were included in this study. The 3-month follow-up data for patient-reported adverse events were scanned. Patient characteristics and parameters are summarized in Tables [1](#pone.0238387.t001){ref-type="table"} and [2](#pone.0238387.t002){ref-type="table"}. Intracranial residual blood, radiologically detected by 5 mm and 1.25 mm CT scans, was taken into account. Moreover, patients were divided into two groups: those suffering from postoperative hemorrhage (PH) and those with hemorrhage necessitating re-operation (PHR). The following parameters were identified as correlated to a) TE or b) PH (Tables [1](#pone.0238387.t001){ref-type="table"} and [2](#pone.0238387.t002){ref-type="table"}):

10.1371/journal.pone.0238387.t001

###### Demographic description and risk factors for thromboembolic events (TE) in operated meningioma patients.

![](pone.0238387.t001){#pone.0238387.t001g}

  Characteristic                                                                        NO (n = 275)                      TE (n = 11[\*](#t001fn001){ref-type="table-fn"})   p-value [\*\*](#t001fn002){ref-type="table-fn"}
  ------------------------------------------------------------------------------------- --------------------------------- -------------------------------------------------- -------------------------------------------------
  **Demographic**                                                                                                                                                            
  **Gender**                                                                            82 M (29.8%)                      3 M (27.3%)                                        1.000
  **193 F (70.2%)**                                                                     8 F (72.7%)                                                                          
  **Age**                                                                               61 ± 13 (50--72)                  71 ± 12 (56--79)                                   0.059
  **BMI**                                                                               26 ±5 (24--29)                    29 ± 4 (26--34)                                    0.059
  **Medical history**                                                                                                                                                        
  **Pre-existing anticoagulation**                                                      39 (14.2%)                        2 (18.2%)                                          0.769
  **Smoker**                                                                            34 (12.4%)                        3 (27.3%)                                          0.164
  **Steroid medication**                                                                145 (52.7%)                       7 (63.6%)                                          0.493
  **Coagulation disorder**                                                              12 (4.4%)                         2 (18.2%)                                          0.095
  **Laboratory values**                                                                                                                                                      
  **Minimum platelet count**                                                            178 ± 59.1 (140--216)             139 ± 32.7 (107--150)                              0.001
  **Minimum hematocrit**                                                                0.301 ± 0.050 (0.273--0.335)      0.223 ± 0.061 (0.206--0.292)                       0.006
  **Minimum INR**                                                                       1.1 ± 5.3 (1.2--1.05)             1.2 ± 5.3 (1.4--1.1)                               0.001
  **Maximum blood pressure**                                                            155/65 ± 22/14 (140/60--170/75)   175/80 ± 20/13 (155/70--190/85)                    Syst: 0.005 Diast: 0.016
  **White blood cell count on admission**                                               7.6 ± 3.4 (6.1--9.7)              8.9 ± 6.1 (7.6--15.8)                              0.025
  **Maximum white blood cell count**                                                    13 ± 6.0 (10--16.7)               16.6 ± 4.6 (15.6--20.5)                            0.01
  **Event**                                                                                                                                                                  
  **Length of surgery**                                                                 269 ± 123.3 (196--356)            373 ± 137.8 (257--518)                             0.015
  **Time point of anticoagulation**                                                     29 ± 21.9 (27--51)                54 ± 69.2 (24--96)                                 0.301
  **Time point of anticoagulation, revised[\*\*\*](#t001fn003){ref-type="table-fn"}**   29 ± 21.9 (27--51)                216± 228 (62--400)                                 0.026

\*2 × DVT, 3 × PE, 4 × DVT+PE, 2 × ischemic stroke

\*\*Metric parameters: U test, ordinal parameters: chi-square test

\*\*\*2 patients were excluded for additional statistical analysis due to immediate TE (see below).

10.1371/journal.pone.0238387.t002

###### Demographic description and risk factors for postoperative hemorrhage (PH) in operated meningioma patients.

![](pone.0238387.t002){#pone.0238387.t002g}

  Characteristic                                 NO (n = 269)                      PH (n = 17)                       p value[\*](#t002fn001){ref-type="table-fn"}
  ---------------------------------------------- --------------------------------- --------------------------------- ----------------------------------------------
  **Demographic**                                                                                                    
  **Gender**                                     78 M (29%)                        7 M (41.2%)                       0.287
  **191 F (71%)**                                10 F (58.8%)                                                        
  **Age**                                        61 ± 13 (50--72)                  67 ± 14 (49--77)                  0.573
  **BMI**                                        27 ±5 (24--30)                    24 ± 3 (24--28)                   0.735
  **Medical history**                                                                                                
  **Pre-existing anticoagulation**               37 (13.8%)                        4 (ASS, 23.5%)                    0.414
  **Smoker**                                     36 (13.4%)                        1 (5.9%)                          0.709
  **Steroid medication**                         136 (50.6%)                       16 (94.1%)                        0.001
  **Coagulation disorder**                       11 (4.1%)                         3 (17.6%)                         0.042
  **Event**                                                                                                          
  **Length of surgery**                          270 ± 122 (192--358)              305 ± 156 (232--454)              0.130
  **Time point of anticoagulation**              29 ± 22.4 (27--50)                69 ± 54 (28--96)                  0.007
  **Time point of event (after surgery) in h**                                     19 ± 16 (15--23)                  
  **Laboratory values**                                                                                              
  **Maximum platelet count**                     267 ± 91.6 (222--321.5)           335 ± 129.4 (256.5--452)          0.013
  **Minimum platelet count**                     177 ± 57.6 (140--215.5)           142 ± 81.0 (119--201.5)           0.106[\*\*](#t002fn002){ref-type="table-fn"}
  **Minimum hematocrit**                         0.301 ± 0.050 (0.273--0.335)      0.246 ± 0.060 (0.204--0.324)      0.011
  **Maximum blood pressure**                     155/65 ± 22/14 (140/60--170/75)   175/80 ± 19/12 (155/60--188/85)   Syst: 0.003 Diast: 0.053
  **White blood cell count on admission**        7.5 ± 3.6 (6.2--9.8)              9.1 ± 3.2 (8.0--11.6)             0.045
  **Maximum white blood cell count**             13 ± 5.6 (10--16.5)               17.6 ± 8.8 (13.2--24.0)           0.003
  **Creatinine on admission**                    70 ± 23.2 (63--81.5)              85 ± 15.4 (67.5--88.5)            0.016
  **Maximum creatinine**                         72 ±27.9 (64--85.5)               90.0 ± 21.8 (76.5--115.5)         0.001
  **Minimum creatinine**                         55 ±14.1 (48--65.5)               52 ± 13.4 (45--65.5)              0.553[\*](#t002fn001){ref-type="table-fn"}

\*Metric parameters: U test, ordinal parameters: chi-square test

\*\*Subgroup analysis of patients with surgically revised hemorrhage (PHR) was performed. In this group, a significant correlation was found for said hemorrhage with minimum platelet count (NO 175 ± 59.2 vs. PHR 120 ± 93.6, p = 0.007, OR 0.989 (CI 0.977--1.002)) as well as minimum creatinine (NO 55 ±14 vs. PHR 45 ± 7.2, p = 0.006, OR 0.939 (CI 0.892--0.990)). The complete subgroup analysis is contained in the appendix.

Epidemiology {#sec013}
------------

286 patients with meningioma who had undergone surgery were analyzed. 11 (3.8%) patients developed thromboembolic events (TE): 7 patients with pulmonary embolism (PE, 2.4%), 6 with deep vein thrombosis (DVT, 2.1%). 2 patients suffered from ischemic stroke (IS, 0.7%). 17 patients (5.9%) suffered from postoperative intracranial hemorrhage (PH), as seen in the mandatory postoperative CT scan or in the event of postoperative neurological deficit, of whom 9 (3.1%) had to be surgically revised (PHR).

There was no significant difference in epidemiological characteristics such as age, BMI or gender. Higher age trended to be correlated with TE, albeit not significantly (p = 0.053).

Time point of prophylactic anticoagulation {#sec014}
------------------------------------------

Patients with delayed prophylactic AC (point of treatment in hours after surgery) were more likely to suffer from TE (NO 29 ± 21.9h, TE 54 ± 69.2, p = 0.301). The OR showed an increased risk for patients with delayed prophylactic anticoagulation of suffering from TE (OR 1.027, CI 1.010--1.043). In the subgroup analysis, 2 patients were found to have suffered from TE immediately after surgery (PE after 2h, DVT after 24h), which changed their course of treatment (immediate therapeutic treatment with low-molecular-weight heparin (LMWH, Tables [3](#pone.0238387.t003){ref-type="table"} and [4](#pone.0238387.t004){ref-type="table"}). We took this significant change in treatment from prophylactic to therapeutic AC into account by excluding these patients and performing additional subgroup analysis regarding the time point of AC and thromboembolic risk. There is, of course, no change in the overall risk of TE after said adjustment; late prophylactic anticoagulation was significantly correlated with thromboembolic events (p = 0.026). The OR was 1.035 (CI 1.015--1.055). Two cases of intracranial hemorrhage were discovered before the administration of anticoagulation (18h and 20h postoperative), which was therefore paused.

10.1371/journal.pone.0238387.t003

###### Patients with TE and time points of anticoagulation.

![](pone.0238387.t003){#pone.0238387.t003g}

  Time point of TE (h after procedure)   Time point of first AC (h after procedure)   Duration of procedure   Type of AC                       Type of TE                     PH/PHR
  -------------------------------------- -------------------------------------------- ----------------------- -------------------------------- ------------------------------ --------------------------
  **2**                                  3                                            338                     Therapeutic heparin (900 U/h)    PE                             
  **24**                                 24                                           396                     Therapeutic heparin (1200 U/h)   DVT                            
  **62**                                 23                                           591                     Prophylactic LMWH                PE                             
  **168**                                96                                           257                     Prophylactic LMWH                Ischemic stroke                Yes, 18h after procedure
  **181**                                24                                           518                     Prophylactic LMWH                PE and DVT                     
  **216**                                72                                           583                     Prophylactic LMWH                PE and DVT                     
  **264**                                54                                           245                     Prophylactic LMWH                Ischemic stroke                
  **400**                                240                                          169                     Prophylactic LMWH                PE and DVT (after discharge)   Yes, 20h after procedure
  **400**                                48                                           453                     Prophylactic LMWH                DVT (after discharge)          
  **567**                                149                                          355                     Prophylactic LMWH                PE                             
  **720**                                96                                                                   Prophylactic LMWH                PE and DVT                     

10.1371/journal.pone.0238387.t004

###### Patients with PH(R) and time point of anticoagulation.
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  Time of PH (CT diagnosis, h postoperative)   Time of first AC (in h postoperative)   Duration of procedure (min)   Surgically revised   Type of AC   TE
  -------------------------------------------- --------------------------------------- ----------------------------- -------------------- ------------ --------------------------------------
  **4**                                        98                                      448                           No                   LMWH         No
  **4**                                        78                                      233                           No                   LMWH         No
  **4**                                        73                                      461                           Yes                  LMWH         No
  **11**                                       69                                      753                           Yes                  LMWH         No
  **18**                                       96                                      257                           No                   LMWH         ischemic stroke (168h postoperative)
  **18**                                       72                                      305                           No                   LMWH         No
  **18**                                       52                                      231                           No                   LMWH         No
  **18**                                       51                                      329                           No                   LMWH         No
  **19**                                       53                                      224                           No                   LMWH         No
  **19**                                       None                                    335                           No                   None         No
  **20**                                       240                                     169                           Yes                  LMWH         DVT and LAE (after discharge)
  **22**                                       112                                     375                           Yes                  UFH          No
  **22**                                       None                                    255                           Yes                  None         No
  **24**                                       28                                      216                           Yes                  LMWH         No
  **40**                                       26                                      504                           Yes                  LMWH         No
  **53**                                       24                                      584                           Yes                  LMWH         No
  **64**                                       26                                      250                           Yes                  LMWH         No

Early AC did not lead to an increased rate of postoperative hemorrhage. By contrast, AC was delayed in patients with PH (in h after surgery: GC 29 ± 22.4, PH 69 ± 54 p = 0.0007; PHR 28 ± 73.7; p = 0.572). OR showed decreased risk of TE and PH in early anticoagulated patients (TE 0.974, CI 0.958--0.990, PH 0.972, CI 0.957--0.988, PHR 0.977 CI 0.961--0.993).

Overall, there were significant differences in the time point of administration.

81.25% of postoperative hemorrhages occurred within 24 hours after surgery. In only 18.75% of cases did bleeding appear on the CT scan after anticoagulation had been administered.

By contrast, only 36.4% of the TE group were anticoagulated within 24 hours after surgery, and of those, 18.2% were given heparin in therapeutic doses.

Patients with coagulation disorder showed increased risk of PH (PH 17.6%, p = 0.042; PHR 33.3%, p = 0.0007).

Multiple logistic regression {#sec015}
----------------------------

For the TE group, we found the following parameters to create the best fit: time point of prophylactic anticoagulation, maximum white blood cell count, white blood cell count on admission, minimum hematocrit, maximum systolic blood pressure, and minimum Quick value (Hosmer--Lemeshow chi-square value = 7.328, p = 0.502). Within this model, the following parameters remained statistically significant: time point of anticoagulation (p = 0.008, OR = 1.029, 95% CI 1.007--1.051), maximum white blood cell count (p = 0.049, OR = 0.834, 95%CI 0.695--0.999), white blood cell count (p = 0.028, OR = 1.246, 95% CI 1.024--1.515), minimum hematocrit (p = 0.021, OR = 0.0001, 95%CI 0.000--0.062).

Three predictors entered the PH model: time point of AC, maximum systolic blood pressure, and steroid usage (Hosmer--Lemeshow chi-square value = 12.415, p = 0.134). However, the only significant variable was the time point of AC (p = 0.042, OR = 1.016, 95%CI 1.001--1.032).

Detailed information on both models can be found in Appendix B.

Outcome {#sec016}
-------

Patients with post-operative TE as well as PH have a worse clinical outcome when analyzed for both GOS (GC 5 ± 0.7 vs. TE 3 ± 1.2 (p = 0.000) vs. PH 4 ± 1.3 (p = 0.002)) and mRS (NO 1 ± 1.2 vs. TE 4 ± 1.9 (p = 0.000) vs. PH 2 ± 1.8 (p = 0.001)). Moreover, TE are associated with a higher risk of reduced functional status than PH (median GOS 3 vs 4, median mRS 4 vs. 2). In-hospital mortality is higher in both subgroups than the no-event group (NO: 2 (0.8%); TE: 2 (18.2%), p = 0.013; PH: 2 (11.8%), p = 0.043) (see [Table 5](#pone.0238387.t005){ref-type="table"}).

10.1371/journal.pone.0238387.t005

###### Differences in outcome parameters for patients suffering from TE and PH.
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  Outcome                     NO (n = 275/269)   TE (n = 11)               PH (n = 17)      
  --------------------------- ------------------ ---------------- -------- ---------------- -------
  **GOS (IQR)**               5 ± 0.7 (4--5)     3 ± 1.2 (3--4)   0.0001   4 ± 1.3 (3--5)   0.002
  **mRS (IQR)**               1 ± 1.2 (0--2)     4 ± 1.9 (2--5)   0.0001   2 ± 1.8 (1--4)   0.001
  **In-hospital mortality**   2 (0.8%)           2 (18.2%)        0.013    2 (11.8%)        0.043
  **Mortality (30 days)**     0                  0                1.000    0                1.000
  **Re-admission**            19 (7.3%)          2 (18.2%)        0.204    2 (11.8%)        0.629

In total, 4 patients died on first admission. Two suffered from pulmonary embolism, one from uroseptic shock in an advanced state of kidney carcinoma, and one from ischemic stroke of unknown origin. No patient died solely from intracranial hemorrhage.

Discussion {#sec017}
==========

Existing data {#sec018}
-------------

To our knowledge, there are no data combining or correlating pre-existing AC, the time point of postoperative AC, and risk factors with PH and TE in patients undergoing craniotomy for meningioma. By contrast, there are data on "early" AC, which indicate the safety of administering anticoagulant agents within 24 hours after the procedure. Unfortunately, in no studies were different time points of AC juxtaposed \[[@pone.0238387.ref016]--[@pone.0238387.ref018]\]. In addition, several studies can be found on patients with various diagnoses in which different AC regimens are compared, such as mechanical vs. chemical prophylaxis or chemical prophylaxis vs. placebo. The results indicate that anticoagulant agents seem to be particularly effective at preventing TE, whereas the hemorrhage rates differ from one study to the next \[[@pone.0238387.ref003], [@pone.0238387.ref019]--[@pone.0238387.ref029]\]. Although studies addressing AC in patients undergoing craniotomy for meningioma exist, they mainly focus on whether or not chemical prophylaxis should be administered \[[@pone.0238387.ref008], [@pone.0238387.ref030]\]. Similarly, we found data on prophylactic treatment in patients operated on for a high-grade glioma \[[@pone.0238387.ref031], [@pone.0238387.ref032]\], as well as data for venous thromboembolism and intracranial hemorrhage after craniotomy for primary malignant brain tumors \[[@pone.0238387.ref033]\] as well as prophylaxis in patients who had undergone decompressive craniectomy \[[@pone.0238387.ref034]\]. Wang et al. elucidated the risk and benefits of heparin usage in adult patients receiving neurosurgery in a systematic review and meta-analysis \[[@pone.0238387.ref035]\]. However, there are no data on specific time points or comparisons of dosage when previous AC treatment is assessed.

Delayed anticoagulation raises the risk of thromboembolic events {#sec019}
----------------------------------------------------------------

Our data clearly indicate that the later AC is performed, the higher the risk of TE. This is consistent with previous findings in which neurosurgical patients showed an increased risk for symptomatic TE, especially due to immobilization and lengthy operative procedures \[[@pone.0238387.ref036], [@pone.0238387.ref037]\]. Risk factors in meningioma patients were highlighted by Nunno et al. \[[@pone.0238387.ref038]\]. The thromboembolism rate of 3.38% is in keeping with our data. However, rates of DVT in screening studies revealed higher rates of asymptomatic TE \[[@pone.0238387.ref039]\]. Pre-existing data revealed a decreased risk for patients with continuous heparin treatment \[[@pone.0238387.ref040]\], although the study compared a combined chemical and mechanical regimen (IPC, leg raise) with subsequent chemical treatment and stockings. Interestingly, this study found no increase in hemorrhage due to continuous heparinization. Regarding the CLOTS trial \[[@pone.0238387.ref041]\], our management rules did not provide for IPC, although other sources found it to be useful in a strictly neurosurgical collective in an RCT \[[@pone.0238387.ref042]\]. We will therefore consider the additional use of IPC in future treatment.

Multiple logistic regression was used to test for independent risk factors for TE. Besides the time point of AC, maximum white blood cell count, white blood cell count on admission, and minimum hematocrit, maximum systolic blood pressure and minimum INR were included in the analysis to obtain the model with the best possible fit.

The time point of AC retains its significance and can therefore be considered an independent risk factor for thromboembolic events (p = 0.008). The OR of 1.029 (95% CI 1.007--1.051) shows that the TE rate increases significantly with subsequent anticoagulation. Other independent risk factors are higher white blood cell count on admission, lower maximum white blood cell count, and low minimum hematocrit. The low number of patients in both the TE and PE group do not provide a good model fit. Even so, the low p value of the time point of anticoagulation is striking. A larger number of patients is necessary for an accurate risk profile.

Two patients were diagnosed with thromboembolic events before the regular administration of heparin. Both were therapeutically anticoagulated immediately with unfractionated heparin. Neither of them suffered from PH ([Table 3](#pone.0238387.t003){ref-type="table"}). On the other hand, anticoagulation was delayed in two patients with PH (96/240h post-op.) because of intracranial bleeding, who both later suffered from thromboembolism. A causal association cannot be established of course in these rare cases.

"Early" anticoagulation does not raise the risk of intracranial hemorrhage {#sec020}
--------------------------------------------------------------------------

The American College of Chest Physicians considers any intracranial operation a procedure with increased risk of bleeding \[[@pone.0238387.ref043]\]. In line with recent data, we found no increase in postoperative hemorrhage after the early administration of LMWH. Moreover, neither heparin administered preoperatively \[[@pone.0238387.ref030]\] nor continuous perioperative administration \[[@pone.0238387.ref040]\] increased the risk of PH. We therefore declare that perioperative prophylactic heparinization in meningioma patients is always safe regarding intracranial hemorrhage. Furthermore, Nittby et al. found that most patients suffering from postoperative hemorrhage had not had any kind of anticoagulation in their study \[[@pone.0238387.ref044]\]. This is consistent with our data, in which only 3 of 17 patients with PH had been anticoagulated between surgery and PH.

In multiple logistic regression to find independent risk factors for PH, only late AC retained its significance. This is because after PH, heparin initiation is usually postponed. No other independent risk factors for PH were found.

Outcome {#sec021}
-------

There were no deaths due solely to postoperative hemorrhage. Two patients died as a direct result of pulmonary embolism: one in uroseptic shock after de-escalation of therapy at the patient's request, the other due to cranial infarction of unknown origin after surgical revision of intracranial hemorrhage. Generally speaking, PH appears to be more treatable and has better survival rates than TE. This also applies to neurological outcome on GOS and mRS, which is less severely lowered by hemorrhage.

Conclusions {#sec022}
===========

In summary, postoperative hemorrhage is mostly a complication of surgery itself or of a pre-existing medical condition, and not of chemical prophylaxis. As surgeons, we tend to exaggerate surgical complications, such as perioperative hemorrhage, because they are inextricably linked to our operative routine. Although both TE and PH do indeed affect patients' outcomes, in our study TE was found to have a far more severe effect on patients' outcomes. Previous data suggested high rates for reduced outcomes for patients with TE \[[@pone.0238387.ref039]\] or PH, but there was no direct comparison to post-hemorrhage outcomes. According to our findings, the definite risks of thromboembolism outweigh the harm caused by postoperative intracranial hemorrhage. This should be considered when deciding postoperative anticoagulation treatment.

To further elucidate anticoagulation management in neurosurgical patients, we therefore propose: i) a prospective randomized study with continuously administered prophylactic AC vs. current regimen, ii) integrating this study with data from different entities, such as glioma, spontaneous and traumatic intracranial hemorrhage. We also suggest prophylactic AC on day 1 after meningioma surgery.

Supporting information {#sec023}
======================

###### 

(XLS)

###### 

Click here for additional data file.
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n.s.

:   not significant

OR

:   odds ratio

PE

:   pulmonic embolism

PH

:   postoperative hemorrhage

PHR

:   postoperative hemorrhage--revised

pTT

:   partial thromboplastin time

s\.

:   see

syst.

:   systolic

TE

:   thromboembolic event

t-test

:   Welch's t-test

UFH

:   unfractionated heparin

U test

:   Mann--Whitney U test

VIF

:   variance inflation factor

WBC

:   white blood cell
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors utilize their retrospective series of patients undergoing craniotomy for meningioma to assess the perioperative use of anticoagulation on patient outcome. The decision to use anticoagulation and timing of initiating/re-initiating anticoagulation following surgery remains a controversial topic without clear consensus. The authors found that delayed initiation of anticoagulation was associated with significantly increased rate of thromboembolic events. Early initiation of did not result in increased rates of post-operative hemorrhage. Additionally, they note that thromboembolic events resulted in poor patient outcomes than post-operative hemorrhage, in their series. I would refer to the authors to the following criticisms:

1\. The organization of this manuscript makes it challenging to adequately assess several important aspects of the study.

2\. The institutional protocol for use and timing of anti-coagulation following surgery is not clearly presented. The reason for delaying anticoagulation and the rationale for resuming anticoagulated needs to be more clearly elaborated upon and presented in a more logical fashion. While this is attempted in the "Practice at our clinical site" portion of the discussion, this should be revised to more appropriately reside in the "Methods" section.

3\. The post-operative imaging protocol is not clearly defined. Do all patients get immediate post-op CTs or at a certain time following surgery?

4\. The positive findings from the regression analyses should have been more clearly explained (or attempted to be explained) in the discussion.

5\. Were the 286 menigioma patients operated on at the same institution/multi-institution?

6\. Table 1 -- thoughts on why blood pressure was 20 points higher on systolic; does this play a role in increased hemorrhage rates? What is the timing of these blood pressures.

Reviewer \#2: I think the language is slightly confusing overall and maybe a good proofreading would help make things more clear.

The introduction talks about what seems to be therapeutic anticoagulation for patients with pre existing conditions and in the abstract it seems like they are talking about perioperative prophylactic anticoagulation for DVT. Can the authors make this more clear.

It is unclear why the tables are set up as control group and the outcome they are looking for Thrombotic event or hemorrhage. They should not use the term control group as this makes it seem like they were stratified. They should just call it no event.

In the results discussing delayed anticoagulation it is unclear if this is therapeutic or prophylactic.

I think in their conclusions they discuss that this is all prophylactic dose but this is important to make clear throughout the manuscript.

I think it seems like the focus is on prophylactic doses the introduction could be better written to reflect data on chemical prophylaxis and make the manuscript more clear that is the focus

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

Multiple Regression has been further discussed (see below).

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

As non native speakers, our abilities are limited. In that regard, we sent the manuscript to a native specializing in revision of scientific literature and we hope to have made the manuscript intelligible.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Review Comments to the Author

Reviewer \#1: The authors utilize their retrospective series of patients undergoing craniotomy for meningioma to assess the perioperative use of anticoagulation on patient outcome. The decision to use anticoagulation and timing of initiating/re-initiating anticoagulation following surgery remains a controversial topic without clear consensus. The authors found that delayed initiation of anticoagulation was associated with significantly increased rate of thromboembolic events. Early initiation of did not result in increased rates of post-operative hemorrhage. Additionally, they note that thromboembolic events resulted in poor patient outcomes than post-operative hemorrhage, in their series. I would refer to the authors to the following criticisms:

1\. The organization of this manuscript makes it challenging to adequately assess several important aspects of the study.

We revised the "Methods" section and placed the therapy regimen and interdisciplinary course of treatment here. We hope that this further elucidates the need for standard protocols, as we lack them. Furthermore we hope to make decision making at our site more clear. We are aware that the variety of endpoints and the organization of the manuscript are challenging. We tried to address this in our revised discussion and to focus on the important conclusions.

2\. The institutional protocol for use and timing of anti-coagulation following surgery is not clearly presented. The reason for delaying anticoagulation and the rationale for resuming anticoagulated needs to be more clearly elaborated upon and presented in a more logical fashion. While this is attempted in the "Practice at our clinical site" portion of the discussion, this should be revised to more appropriately reside in the "Methods" section.

Unfortunately, the lack of any institutional protocol sparked this investigation. We tried to further elucidate the decision making process regarding AC and put it in the "Methods" section, were it absolutely should reside. Again, we have difficulties to point out a clear concept or algorithm. nonetheless the variety of different therapy regimen allowed us to investigate the influence of different timepoints of AC. The section added reads as follows:

Patients were anticoagulated based on national guidelines \[14, 15\], known independent risk factors and preexistent diseases. Time-point and dose as well as the choice of substance were chosen according to hospital's guidelines and in interdisciplinary bed-side discourse with intensive care and neurosurgical practitioners. However, anticoagulation in this study did not follow a definite protocol, which provides the variety of timepoints and therapy regimen that we were able to examine. The common course of treatment and diagnostic can be described as follows:

Patients are not anticoagulated until a CT scan has been performed. CT scans on the first postoperative day are routine (within 24h after surgery). Upon new neurological deficits CT-scans are performed immediately.

We began prophylactic AC treatment in patients undergoing intracranial surgery on the first day after surgery, as far as postoperative CT-scans do not show any signs of residual bleeding. Patients with postoperative or perioperative hemorrhage are mainly anticoagulated after 3-5 days, after a repetitive CT-scan without any sign of a growing hemorrhage.

In patients with preoperative regimen of DOAC or NOAC, an interruption of therapy up to 3 weeks was carried out, dependent on indication, during the examined period of time. In those cases, heparin-bridging was regularly undertaken.

Since 2014, a standard operating procedure states that hospitalized tumor patients should be considered for anticoagulation as long as there are no contraindications, in which case mechanical prophylaxis or no prophylaxis at all should be applied. We adapted the regimen and are currently halting preexisting AC until suture's removal, if no urgent indication exists.

3\. The post-operative imaging protocol is not clearly defined. Do all patients get immediate post-op CTs or at a certain time following surgery?

Patients are routinely scanned on the day following surgery. This is usually done "the next morning" between 8am and 12am, depending on ICUs capacity to oversee CT-transport. We overlooked the data and CT scans are exactly tracked with timestamps in our data. From that we can conclude, that they were all undertaken within 24h after surgery (at least). In case of new neurological deficits, CT-scans were performed immediately as emergency diagnostic. In brief we summarized for the manuscript:

Patients are not anticoagulated until a CT scan has been performed. CT scans on the first postoperative day are routine (within 24h after surgery). Upon new neurological deficits CT-scans are performed immediately.

4\. The positive findings from the regression analyses should have been more clearly explained (or attempted to be explained) in the discussion.

Absolutley. The most important positive finding is th persistence of late AC timepoints as independent risk factor, in our opinion. Therefore we added the following sections:

In: "Delayed anticoagulation increases risk of thromboembolic events"

Multiple logistic regression was used to test for independent risk factors for TE. Besides timepoint of AC, maximum white blood cell count, white blood cell count at admission, minimum hematocrit, maximum systolic blood pressure and minimum Quick -- value entered the analysis to achieve the model with the best possible fit.

Timepoint of AC remains its significance and can therefore be considered an independent risk factor for thromboembolic events (p=0.008). The Odd's Ratio of 1.029 (95% CI 1.007-1.051) displays that the TE rate increases significantly with later anticoagulation. Other independent risk factors are higher white blood cell count at admission, lower maximal white blood cell count (?) and low minimal hematocrit.

The low number of patients in both, the TEE and PE group, do not make for a good model fit. Still, the low p-value of the timepoint of anticoagulation is striking. But a larger number of patients is necessary for an accurate risk profile.

And in: "Early" anticoagulation does not increase the risk of intracranial hemorrhage

In multiple logistic regression to find independent risk factors for PH, only late AC retained its significance. This is because after PH heparin initiation is usually postponed. Other independent risk factors for PH could not be found.

5\. Were the 286 menigioma patients operated on at the same institution/multi-institution?

All in the same institution. We added the hospital in the following passage:

The digital database of the University Hospital Leipzig for all patients with the histopathological diagnosis of meningioma, who underwent surgery in 2012-2018 and operated in the Department of Neurosurgery, University Hospital Leipzig, was searched.

6\. Table 1 -- thoughts on why blood pressure was 20 points higher on systolic; does this play a role in increased hemorrhage rates? What is the timing of these blood pressures.

Yes a very interesting finding, which we spent a lot of time investigating, actually. We first correlated high blood pressure and PH rates, then saw it prevail in multiple regression. We then correlated the time of blood pressure peaks to 1.) time point of bleeding and blood pressure peak and time of bleeding and 2.) time point of blood pressure peak after surgery (we performed the same for hematocrit, pTT, INR etc.). The result was chaotic, yet clear: There is no association whatsoever between WHEN the peak happens and WHEN the bleeding happens. We then assessed blood pressure ad admission, to also find a (weaker) correlation. We therefor concluded: The disposition for high blood pressure in general (due to comorbidities) is a risk factor for rebleeding, regardless of certain "peaks". We know the data is insufficient and we would need 1.) continuous blood pressure measurement data, 2.) blood-pressure-curve analyses a.s.o. We did not include this in the paper due to the large amount of data and figures it would need to explain but we have the topic and mind and will further investigate and, if the data is consistent, publish separately. For our objective of AC we found it not be too relevant.

Reviewer \#2:

1\. I think the language is slightly confusing overall and maybe a good proofreading would help make things more clear.

As non native speakers, our abilities are limited. In that regard, we sent the manuscript to a native specializing in revision of scientific literature and we hope to have made the manuscript intelligible.

2\. The introduction talks about what seems to be therapeutic anticoagulation for patients with pre existing conditions and in the abstract it seems like they are talking about perioperative prophylactic anticoagulation for DVT. Can the authors make this more clear.

We revised the very first sentence to mention AC as follows:

In perioperative treatment of patients undergoing intracranial surgery we face opposed poles: The necessity for prophylactic AC and its most feared adverse effect, intracranial hemorrhage.

We hope to set the goal of this study right at the beginning! Secondly we added the following passage, to make clear, that preexisting AC is not examined, but is an additional risk factor and underlines the necessity of proper prophylactic AC:

Neurosurgical patients are at high risk for thromboembolism of any kind due to immobilization and length of surgery. Additionally, Ddue to demographic changes, making cardiovascular diseases more prevalent, increasing numbers of significantly anticoagulated patients are observed \[4\]. A survey conducted by Skardelly et al. concluded that in 2016 nearly two thirds of the German neurosurgical departments had not yet defined an algorithm regarding continuous, discontinuous or bridged anticoagulant and antiplatelet therapy during elective surgery.

It is unclear why the tables are set up as control group and the outcome they are looking for Thrombotic event or hemorrhage. They should not use the term control group as this makes it seem like they were stratified. They should just call it no event.

Absolutely, ther was no prospective investigation and no negative control. We called the group "no event" and used the abbreviation "NO".

In the results discussing delayed anticoagulation it is unclear if this is therapeutic or prophylactic.

We clarified in the text:

Time - point of Prophylactic Anticoagulation

Patients with delayed prophylactic AC (point of treatment in hours after surgery) were more likely to suffer from TE (CGNO 29 ± 21.9h, TE 54 ± 69.2, p=0.301).

The switch to therapeutic anticoagulation in 2 cases of early postoperative pulmonary embolism is indeed statistically problematic. We tried to address this in the section below the passage mentioned.

I think in their conclusions they discuss that this is all prophylactic dose but this is important to make clear throughout the manuscript.

Asolutely! We added the "prophylactic" in all places were it needed clarification.

I think it seems like the focus is on prophylactic doses the introduction could be better written to reflect data on chemical prophylaxis and make the manuscript more clear that is the focus

Now that you point it out, we agree clearly. We differentiated between prophylactic when and wherever necessary.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
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Jonathan H Sherman

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have addressed the concerns that were brought up in the revision requests. Satisfied with the responses.

Reviewer \#2: The authors have addressed all the comments adequately I have no issue with this being published.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: **Yes: **Walavan Sivakumar

Reviewer \#2: No
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Dear Dr. Wilhelmy:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.
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PLOS ONE Editorial Office Staff
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